SCHEMBL723557

SCHEMBL723557

Cn1cc(-c2ccnc3cc(-c4cccc(OCc5ccccc5)c4)oc23)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.48
PRKDC P78527 2/20 0.43
ATM Q13315 1/20 0.43
AURKB Q96GD4 3/20 0.41
AURKA O14965 1/20 0.41
INCENP Q9NQS7 1/20 0.41
TPX2 Q9ULW0 1/20 0.41
PRMT5 O14744 3/20 0.41
MPO P05164 1/20 0.39
WDR77 Q9BQA1 1/20 0.38
MAOB P27338 1/20 0.38
F2RL3 Q96RI0 1/20 0.38
LRRK2 Q5S007 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
CYP11B1 P15538 1/20 0.37
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724763 0.94 IRAK1 (0.41) GRM4PRKDCATMAURKBAURKA
SCHEMBL16817174 0.85 PRKDC (0.43) GRM4PRKDCATMPRMT5MPO
SCHEMBL721430 0.83 AURKB (0.46) AURKBAURKAINCENPTPX2
SCHEMBL724285 0.81 ALK (0.52)
SCHEMBL10268949 0.80 AURKB (0.46) AURKBAURKAINCENPTPX2LRRK2
SCHEMBL721974 0.80 MAP3K7 (0.44) AURKBAURKAINCENPTPX2LRRK2
SCHEMBL725386 0.78 PFKFB3 (0.39) AURKBAURKAINCENPTPX2FGFR2
SCHEMBL723918 0.78 PDE4C (0.46) MAOB
SCHEMBL725506 0.77 KCNH2 (0.43) GRM4AURKBAURKAINCENPTPX2
SCHEMBL724751 0.77 MAP3K7 (0.47) AURKBAURKAINCENPTPX2LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB GRM4 4357/4885PRKDC 180/4885ATM 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.